



Express Mail Label No.

Dated: _____

Docket No.: 05432/100L600-US1
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Patent Application of:
Arne Mork et al.

Application No.: 10/516,519

Confirmation No.: 4458

Filed: November 29, 2004

Art Unit: Not Yet Assigned

For: COMBINATION THERAPY WHEREIN A
SEROTONIN REUPTAKE INHIBITOR IS
USED

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

A copy of each document on the PTO/SB/08 is attached.

References BG and CB were cited in the International Search Report of the corresponding PCT application. A copy of the International Search Report is attached.

{W:\05432\100\600US1\00407473.DOC [REDACTED]}

The PTO did not receive the following
listed item(s) Any references that
attached on PTO/SB/08


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.


No fee is believed due with this submission. If, however, a fee is due, the Commissioner is authorized to charge it up to \$300.00 to Deposit Account No. 04-0100.

Dated: April 14, 2005

Respectfully submitted,

By 
Jay P. Lessler

Registration No.: 41,151
DARBY & DARBY P.C.
P.O. Box 5257
New York, New York 10150-5257
(212) 527-7700
(212) 527-7701 (Fax)
Attorneys/Agents For Applicant



04-18-05
JC03 Rec'd PCT/PTO 14 APR 2005

PCT

Application No. (if known): 10/516,519

Attorney Docket No.: 05432/100L600-US1

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. _____ in an envelope addressed to:

EU 447562375-us

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on April 14, 2005
Date

B.W. Lee

Signature

B.W. Lee


Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2 pp); with
25 References attached
Information Disclosure Statement (2 pp)
Postcard



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/516,519/Conf. #: 4458
				Filing Date	November 29, 2004
				First Named Inventor	Arne Mork
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	05432/100L600-US1


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	EP-0687472		20/12/95	Wong et al..	
BB	EP-0701819		20/03/96	Chenard et al..	
BC	EP-0714633		05/06/96	Ogulza et al.	
BD	WO-9603400		08/02/96	Macor et al.	
BE	WO-9728141		07/08/97	Halazy et al.	
BF	WO-9913877		25/03/99	Berg et al.	
BG	WO-9937303		29/07/99	Dawson et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
CA	Kamatchi et al., <i>Brain, Research</i> , 586:181-186 (1990) "GABA _A receptor activation inhibits Ca ²⁺ -activated ⁸⁶ Rb-efflux in cultured spinal cord neurons via G-protein mechanism".				
CB	Londborg et al., <i>Journal of Affective Disorders</i> (2000) 61:73-79, "Short-term cotherapy with clonazepam and fluoxetine: anxiety, sleep disturbance and core symptoms of depression".				
CC	Blier et al., <i>TiPS</i> , 15:220-226 (July 1994); "Current advances and trends in the treatment of depression"				
CD	Paredes et al. <i>Neuroscience and Biobehavioral Reviews</i> , Vol. 16 pp. 145-170 (1992), "GABA and Behavior: The Role of Receptor Subtypes"				
CE	Hjorth, <i>J. of Neurochemistry</i> (1993) pp. 776-779, "Serotonin 5-HT _{1A} Autoreceptor Blockade Potentiates the Ability of the 5-HT Reuptake Inhibitor Citalopram to Increase Nerve Terminal Output of 5-HT In Vivo: A Microdialysis Study"				

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
				Application Number	10/516,519/Conf. #: 4458
				Filing Date	November 29, 2004
				First Named Inventor	Arne Mork
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	05432/100L600-US1

	CF	Tao et al., <i>J. Psychopharmacology</i> 14(2)(2000) pp. 100-113, "Regulation of serotonin release by GABA and excitatory amino acids"	
	CG	F. Artigas, <i>TiPS</i> - July 1993) (Vol. 14); "Letters - 5-HT and antidepressants: new views from microdialysis studies".	
	CH	Haefely, <i>Experimental Approaches to Anxiety and Depression</i> ; (1992); pp. 151-168, "The Role of GABA in Anxiolytic/Antidepressant Drug Action"	
	CI	Frydenvang, et al., <i>Chirality</i> 6:583-589 (1994) "GABA _B Antagonists: Resolution, Absolute Stereochemistry, and Pharmacology of (R)- and (S)Phaclofen"	
	CJ	Bowery, et al., <i>Pharmacol. Reviews</i> ; 54:247-264 (2002) Vol. 54, No. 2, "International Union of Pharmacology. XXXIII. Mammalian γ -Aminobutyric Acid _B Receptors: Structure and Function"	
	CK	Karla, <i>J. Med. Chem.</i> (1999) 42, pp. 2053-2059, "Synthesis and Pharmacology of Baclofen Homologues 5-Amino-4-(4-chlorophenyl)pentanoic Acid and the R- and S-Enantiomers of 5-Amino-3-(4-chlorophenyl)pentanoic Acid"	
	CL	Brauner-Osborne et al., <i>British J. Pharmacology</i> (1999) 128, 1370-1374, "Function pharmacology of cloned heterodimeric GABA _B receptors expressed in mammalian cells"	
	CM	Innis et al., <i>Europ. J. of Pharmacology</i> , 143 (1987) pp. 195-204, "Pertussis toxin blocks 5-HT _{1A} and GABA _B receptor-mediated inhibition of serotonergic neurons"	
	CN	Ivernizzi et al., <i>Brain Research</i> , 584 (1992) 322-324, "Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex"	
	CO	Tao et al., <i>British J. Pharmacology</i> (1996) 119, 1375-1384, "Differential regulation of 5-hydroxytryptamine release by GABA _A and GABA _B receptors in midbrain raphe nuclei and forebrain of rats"	
	CP	Gartside et al., <i>British J. Pharmacology</i> (1995) 1064-1070, "Interaction between a selective 5-HT _{1A} receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT"	
	CQ	Blier et al., <i>J. Clinical Psychopharmacology</i> (1987) Vol. 7, pp. 24S - 35S, "Modifications of the Serotonin System by Antidepressant Treatments: Implications for the Therapeutic Response in Major Depression"	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner's Signature		Date Considered	
----------------------	--	-----------------	--